PL2622078T3 - Białko fuzyjne dla ekspresji białka wydzielniczego - Google Patents

Białko fuzyjne dla ekspresji białka wydzielniczego

Info

Publication number
PL2622078T3
PL2622078T3 PL11763647T PL11763647T PL2622078T3 PL 2622078 T3 PL2622078 T3 PL 2622078T3 PL 11763647 T PL11763647 T PL 11763647T PL 11763647 T PL11763647 T PL 11763647T PL 2622078 T3 PL2622078 T3 PL 2622078T3
Authority
PL
Poland
Prior art keywords
protein
secretory
expression
fusion protein
fusion
Prior art date
Application number
PL11763647T
Other languages
English (en)
Inventor
Joen Luirink
Wouter S P Jong
Original Assignee
Abera Bioscience Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abera Bioscience Ab filed Critical Abera Bioscience Ab
Publication of PL2622078T3 publication Critical patent/PL2622078T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL11763647T 2010-09-28 2011-09-28 Białko fuzyjne dla ekspresji białka wydzielniczego PL2622078T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1051000 2010-09-28
EP11763647.2A EP2622078B1 (en) 2010-09-28 2011-09-28 Fusion protein for secretory protein expression
PCT/EP2011/066854 WO2012041899A1 (en) 2010-09-28 2011-09-28 Fusion protein for secretory protein expression

Publications (1)

Publication Number Publication Date
PL2622078T3 true PL2622078T3 (pl) 2015-05-29

Family

ID=44719941

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11763647T PL2622078T3 (pl) 2010-09-28 2011-09-28 Białko fuzyjne dla ekspresji białka wydzielniczego

Country Status (7)

Country Link
US (1) US9322011B2 (pl)
EP (1) EP2622078B1 (pl)
CN (1) CN103228787B (pl)
CA (1) CA2811699C (pl)
ES (1) ES2529442T3 (pl)
PL (1) PL2622078T3 (pl)
WO (1) WO2012041899A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201009861D0 (en) * 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9808517B2 (en) 2012-04-06 2017-11-07 Cornell University Subunit vaccine delivery platform for robust humoral and cellular immune responses
SG11201500171YA (en) * 2012-07-10 2015-02-27 Transgene Sa Mycobacterial antigen vaccine
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
BR112017025954A2 (pt) * 2015-06-02 2018-08-14 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport apresentação em superfície de antígenos em vesículas de membrana externa gram-negativa
EP3701009B1 (en) 2017-10-25 2024-12-18 Abera Bioscience AB Display of heterologous molecules on bacterial cells and membrane vesicles
GB202009411D0 (en) * 2020-06-19 2020-08-05 Prokarium Ltd Autotransporter systems
EP3981879A1 (en) * 2020-10-09 2022-04-13 Stada Arzneimittel Ag Method of producing a recombinant protein in a host cell which has a disabled rhamnose metabolism as well as expression vectors, host cells and recombinant proteins thereof
US12649150B2 (en) 2024-05-29 2026-06-09 Cassiopea LLC Enzyme-decorated nanocatalysts

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59611241D1 (de) * 1996-03-15 2005-08-04 Max Planck Gesellschaft Exportsysteme für rekombinante proteine
US20040259151A1 (en) * 2001-03-02 2004-12-23 Joachim Jose Functional surface display of polypeptides
GB0220199D0 (en) * 2002-08-30 2002-10-09 Univ Utrecht Mutant protein and refolding method
CN1674933B (zh) * 2002-08-02 2012-09-26 葛兰素史密丝克莱恩生物有限公司 疫苗组合物
AU2003901316A0 (en) 2003-03-21 2003-04-03 The Royal Alexandra Hospital For Children Regulation of cell surface proteins
AU2004277342B2 (en) * 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination
US7628995B2 (en) * 2003-12-23 2009-12-08 Glaxosmithkline Biologicals S.A. Outer membrane vesicles and uses thereof
ES2301262B1 (es) * 2004-01-14 2009-05-29 Consejo Sup. Investig. Cientificas Generacion de adhesion especifica en bacterias gram negativas mediante el anclaje de monodominos de inmunoglobulinas en su superficie con autotransportadores.
US8029777B2 (en) * 2004-08-13 2011-10-04 Marshall Barry J Helicobacter system and uses thereof
US9259463B2 (en) * 2006-01-16 2016-02-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chlamydia vaccine
US8293685B2 (en) * 2007-07-26 2012-10-23 The Regents Of The University Of California Methods for enhancing bacterial cell display of proteins and peptides
EP2475772B1 (en) * 2009-09-09 2017-04-12 Autodisplay Biotech GmbH A method for binding a recombinant polypeptide to a carrier
US8771669B1 (en) * 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
CA2792691A1 (en) * 2010-03-11 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition or vaccine against gram-negative bacterial, for example, neisserial, infection or disease
EP2619306B1 (en) * 2010-09-23 2015-05-20 Autodisplay Biotech GmbH Surface display of polypeptides containing a metal porphyrin or a flavin

Also Published As

Publication number Publication date
US9322011B2 (en) 2016-04-26
CN103228787B (zh) 2017-06-23
HK1187369A1 (en) 2014-04-04
CA2811699C (en) 2019-07-02
EP2622078A1 (en) 2013-08-07
EP2622078B1 (en) 2014-11-05
US20130344099A1 (en) 2013-12-26
CN103228787A (zh) 2013-07-31
CA2811699A1 (en) 2012-04-05
ES2529442T3 (es) 2015-02-20
WO2012041899A1 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
SG10202100341XA (en) Npp1 fusion proteins
IL232743A0 (en) anticancer fusion protein
EP2729488A4 (en) PROCESS FOR PREPARING MULTIMANT POLYPEPTIDES
ZA201300677B (en) Anticancer fusion protein
PL3321287T3 (pl) Białka fuzyjne oraz szczepionki skojarzone
EP2772230A4 (en) FUSION GRAFT
ZA201303449B (en) Anticancer fusion protein
EP2698386B8 (en) Fusion protein
SI2661496T1 (sl) Fuzijski protein proti raku
ZA201405460B (en) Anticancer fusion protein
EP2657337A4 (en) FUSION PROTEIN
ZA201308597B (en) Anticancer fusion protein
ZA201207425B (en) Fusion protein
GB201007955D0 (en) Somatosatin fusion proteins
GB201107189D0 (en) Fusion proteins
GB201114701D0 (en) Fusion proteins
AU2011905145A0 (en) Fusion Protein
GB201104152D0 (en) Fusion Polypeptide
GB201007550D0 (en) Modified receptor fusion proteins
GB201004150D0 (en) Modified receptor fusion proteins
GB201010202D0 (en) Fusion polypeptides
HUP1100282A2 (en) Protein factor
PL393146A1 (pl) Przeciwnowotworowe białko fuzyjne
GB201103169D0 (en) Protein expression
GB201005062D0 (en) Antibodies